Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
Saved in:
| Title: | Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates. |
|---|---|
| Authors: | Salamat-Miller N; Process Development, Formulation Development, Takeda, Lexington, MA, USA. Electronic address: nazila.miller@takeda.com., Qu W; BioAnalytix, Cambridge, MA, USA., Chadwick JS; BioAnalytix, Cambridge, MA, USA., McPherson C; Department of Pediatrics, Washington University, St. Louis, MO, USA., Salinas PA; Analytical Development-Biologics-US, Takeda, Lexington, MA, USA., Turner M; Institute of Translational Medicine, University of Liverpool, Liverpool, UK., Wang D; BioAnalytix, Cambridge, MA, USA., Barton N; Global Clinical Development, Rare Metabolic Diseases, Takeda, Lexington, MA, USA. |
| Source: | Journal of pharmaceutical sciences [J Pharm Sci] 2022 May; Vol. 111 (5), pp. 1486-1496. Date of Electronic Publication: 2021 Oct 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
